CHOP plus Rituximab — Balancing Facts and Opinion
- 24 January 2002
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 346 (4) , 280-282
- https://doi.org/10.1056/nejm200201243460411
Abstract
Research on the treatment of the non-Hodgkin's lymphomas has finally emerged from decades of stagnation. These lymphomas, which usually arise from B lymphocytes, are the fifth most common type of cancer in the United States and are the fifth and sixth leading cause of death from cancer in men and women, respectively.1 Approximately 25 to 30 percent of non-Hodgkin's lymphomas have an indolent course; the remainder are aggressive tumors. For 25 years, the standard treatment for diffuse large-B-cell lymphoma, the most common of the aggressive non-Hodgkin's lymphomas, has been a regimen of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), which cures . . .Keywords
This publication has 11 references indexed in Scilit:
- CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell LymphomaNew England Journal of Medicine, 2002
- Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-Refractory Low-Grade or Transformed Low-Grade B-Cell Non-Hodgkin’s LymphomasJournal of Clinical Oncology, 2001
- Cancer Statistics, 2001CA: A Cancer Journal for Clinicians, 2001
- Phase I/II Trial of IDEC-Y2B8 Radioimmunotherapy for Treatment of Relapsed or Refractory CD20+B-Cell Non-Hodgkin's LymphomaJournal of Clinical Oncology, 1999
- Treatment of Patients With Low-Grade B-Cell Lymphoma With the Combination of Chimeric Anti-CD20 Monoclonal Antibody and CHOP ChemotherapyJournal of Clinical Oncology, 1999
- Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.Journal of Clinical Oncology, 1998
- IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's LymphomaBlood, 1997
- Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphomaBlood, 1994
- Comparison of a Standard Regimen (CHOP) with Three Intensive Chemotherapy Regimens for Advanced Non-Hodgkin's LymphomaNew England Journal of Medicine, 1993
- Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy.Journal of Clinical Oncology, 1993